Alleviant Medical develops a no-implant shunt therapy designed to alleviate the clinical and economic burden of heart failure. The Alleviant System, which has received Breakthrough Device Designation from the U.S. FDA, aims to improve patient outcomes and reduce healthcare costs associated with heart failure management.

Apella Technology offers an AI-powered surgical operations platform that enhances real-time decision-making and operational efficiency in the operating room. By providing predictive insights on case durations and staffing needs, the platform reduces administrative complexity and improves surgical workflow, leading to a 24% increase in surgery duration predictions compared to traditional electronic health records.

Artelon provides FLEXBAND, a bio‑engineered implant that augments repaired ankle ligaments and tendons with elastic, load‑sharing support. Its patented porous material maintains soft‑tissue tension during dynamic motion while promoting rapid cellular infiltration and full tissue integration over 4–6 years, helping patients regain stable, functional mobility.

The company provides a High‑Definition PCR (HDPCR™) platform that delivers over four‑fold multiplexing of DNA and RNA biomarkers using standard PCR instruments, enabling comprehensive genomic profiling without dedicated hardware. Its cloud‑based analytics suite automates assay interpretation, quality control, and reporting in a HIPAA‑ and ISO‑compliant environment, offering a faster, lower‑cost alternative to NGS for oncology, MRD, and disease‑monitoring applications in clinical laboratories.

Cleerly is a digital healthcare company that utilizes AI-based analysis of coronary computed tomography angiography (CCTA) imaging to quantify and characterize atherosclerosis, enabling precise identification of heart disease. This approach addresses the issue that over 70% of heart attack victims are misclassified as low risk by traditional methods, allowing for earlier and more personalized treatment plans.

Elucent Medical develops a breast cancer detection system that utilizes SmartClip technology and the EnVisio Navigation system to accurately locate tumor margins in real-time during surgical excision. This approach eliminates the need for metal clips, enhances surgical precision, and minimizes tissue removal, ultimately improving patient outcomes and satisfaction.

Evident Vascular provides the Evident™ intravascular ultrasound (IVUS) platform, a high‑resolution imaging system optimized for peripheral arterial and deep venous procedures. The platform uses AI‑driven image enhancement and automatic vessel segmentation to deliver clearer visualizations and streamlined workflow integration, enabling clinicians to size devices more accurately, assess stent expansion, and detect complications in real time.

FIRE1 is developing novel therapeutic devices aimed at enhancing patient outcomes through targeted delivery mechanisms. The startup addresses the need for more effective treatment options in the medical device sector, focusing on improving therapeutic efficacy and patient compliance.

Inari Medical develops specialized medical devices for the interventional treatment of cardiovascular diseases, focusing on thrombectomy and venous interventions. Their technology aims to improve patient outcomes by effectively removing blood clots and restoring blood flow in affected vessels.

The startup develops neuromodulation devices and software that deliver targeted electrical stimulation to specific brain and spinal cord areas, providing a less invasive treatment option for patients with chronic diseases. This technology enhances therapeutic effectiveness and expands access to care for a broader patient population.

Luna Diabetes provides automated insulin delivery specifically designed for individuals using insulin pens during sleep. This system uses micro-boluses to maintain optimal glucose control overnight without requiring a traditional insulin pump. The technology allows users to maintain their existing Multiple Daily Injection (MDI) regimen while achieving worry-free nighttime glucose management.

Metavention provides a minimally invasive renal (and hepatic) denervation procedure using its proprietary iRF Denervation System, which delivers radio‑frequency energy with integrated cooling to permanently disrupt overactive sympathetic nerves. The one‑time outpatient treatment aims to lower blood pressure and improve metabolic parameters in patients with resistant hypertension or uncontrolled type 2 diabetes, offering an alternative to additional medication.

Moxe provides an EHR‑neutral, API‑first interoperability platform that automates the secure exchange of clinical data between providers and payers. The service encrypts data, normalizes it into standardized formats for use cases such as risk adjustment, payment integrity and care management, and offers real‑time dashboards and role‑based portals for monitoring and analytics.

Nyra Medical offers the Cardiac Leaflet Enhancer (CARLEN), a transcatheter, single‑leaflet nitinol clip that augments the length and thickness of the mitral valve leaflets to treat functional (secondary) mitral regurgitation. Delivered via a transfemoral, transseptal approach under imaging guidance, CARLEN preserves native valve geometry, is reversible, and expands treatment eligibility for patients who are ineligible for existing edge‑to‑edge repair systems.

Okami Medical offers the LOLO Vascular Occlusion System, a single‑device embolization solution that uses HD BRAID® high‑density mesh to achieve rapid, complete flow cessation in peripheral vessels 1.5–9 mm. Integrated with low‑friction SENDERO® delivery catheters, the system provides precise placement, MR‑conditional safety, and minimal imaging artifact, reducing procedure time and material use.

Personal Genome Diagnostics provides kitted, end‑to‑end comprehensive genomic profiling solutions for solid tumor tissue and liquid biopsy samples that can be run in‑house. Their FDA‑cleared and CE‑IVD marked elio kits cover 500+ cancer‑related genes and include an automated bioinformatics pipeline that delivers clinical‑grade reports in as few as five days, enabling laboratories to obtain rapid, reliable genomic insights and support personalized cancer treatment decisions.

Rampart IC develops the Defender, a portable radiation shielding system that provides full-body protection for interventionalists and technicians without the burden of heavy lead aprons. This system features adjustable panels and multiple vascular access points, significantly reducing the risk of work-related injuries and enhancing mobility in crowded cath labs.

Senseonics offers the Eversense implantable continuous glucose monitoring system, embedding a small sensor under the skin to provide real‑time glucose readings for up to 365 days (or 180 days) via a rechargeable Bluetooth transmitter and companion mobile app. The platform removes the need for daily sensor changes, minimizes adhesive‑related skin irritation, and delivers clinically calibrated data with HIPAA‑compliant cloud storage for clinician access.

Provides an intraocular drug delivery platform that integrates with intraocular lenses (IOLs) to release bimatoprost continuously for up to three years, treating glaucoma in patients undergoing cataract surgery. This system addresses patient non-adherence to topical medications, reducing the risk of disease progression and vision loss by ensuring consistent, long-term intraocular pressure control.

Vesper Medical develops the Vesper DUO Venous Stent System®, engineered to address the anatomical challenges of the deep venous system in patients with Chronic Venous Insufficiency (CVI). This next-generation stent portfolio reduces the need for multiple stent types in the iliofemoral segment, streamlining treatment and improving patient outcomes.

Volta Medical develops AI-driven software that assists cardiologists by analyzing electrophysiology data during interventional procedures. This technology enhances procedural accuracy and decision-making, ultimately improving patient outcomes in cardiac care.